中核国际(02302.HK)中期纯利减少56.48%至228.3万港元
格隆汇8月29日丨中核国际(02302.HK)公布,截至2019年6月30日止六个月,实现收入11.88亿港元,同比增长65.42%;毛利1507.2万港元,同比增长142.9%;公司拥有人应占期内溢利228.3万港元,同比减少56.48%;每股基本盈利0.47港仙;不派息。
公告称,集团录得天然铀及供应链贸易业务收入约11.88亿港元,相比去年同期收入大幅增长。收入大幅增长由于电子产品及其他产品贸易业务收入增长所致。
期内,录得净利润约228.3万港元。
据悉,净利润低于2018年同期,乃由于(i)投资中核融资租赁有限公司所产生的融资成本;及(ii)回顾期内并无税务拨备回拨。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.